by Richard Daverman, PhD
March 30, 2013 --
Sinopharm Group raised $515 million to fund its growth in the China drug distribution sector by selling new shares, adding to the $640 million it raised in bonds earlier this month; SK Biopharma of South Korea will collaborate with two China companies to develop its novel CNS drug; Weihai Weigao Medical Devices will distribute TriReme Medical’s portfolio of cardiovascular devices; China’s Ministry of Health issued a new essential medicine list with 520 products, up from 307 in the 2009 list; General Electric Healthcare will double production of its medical imaging devices in China; Agenix of Australia expects to file a China clinical trial application for its hepatitis B drug candidate by June; Life Technologies received SFDA approval of an Applied Biosystems sequencer while its JV with Daan Gene develops 10 diagnostic assays for use on the machine; and Cellular Biomed started a China clinical trial of a personalized treatment for liver cancer. More details….
Stock Symbols: (HK: 1099) (HK: 1066) (NYSE: GE) (ASX: AGX) (NSDQ: LIFE) (OTCQB: CBMG)